Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Clinical Trial Innovation

Laura Esserman

劳拉·埃斯曼

MD, MBA

🏢University of California, San Francisco (UCSF)(加利福尼亚大学旧金山分校)🌐USA

Professor of Surgery and Radiology; Director, UCSF Breast Care Center; I-SPY 2 Principal Investigator外科学与放射学教授;UCSF乳腺癌诊疗中心主任;I-SPY 2首席研究员

65
h-index
2
Key Papers
4
Awards
2
Key Contributions

👥Biography 个人简介

Laura Esserman, MD MBA is a visionary surgical oncologist and the principal investigator of the I-SPY 2 Trial at UCSF, the world's most prominent adaptive neoadjuvant breast cancer platform trial. She champions transformative clinical trial innovation, integrating MRI biomarkers and molecular profiling to accelerate drug approval.

Share:

🧪Research Fields 研究领域

I-SPY 2 Adaptive Platform TrialI-SPY 2适应性平台试验
Neoadjuvant Breast Cancer Trials新辅助乳腺癌试验
Platform Trials平台试验
Breast Cancer Precision Oncology乳腺癌精准肿瘤学
Biomarker-Driven Trial Design生物标志物驱动试验设计

🎓Key Contributions 主要贡献

I-SPY 2 Adaptive Platform Trial

Led I-SPY 2, a groundbreaking FDA-supported adaptive platform trial simultaneously evaluating multiple investigational agents in neoadjuvant breast cancer, using pathological complete response as a surrogate endpoint.

Neoadjuvant Trial Innovation

Pioneered the use of neoadjuvant therapy as a platform for rapid biomarker validation and drug evaluation, enabling multiple drugs to graduate to phase III trials based on adaptive Bayesian analysis.

Representative Works 代表性著作

[1]

Pathological Complete Response Predicts Long-Term Survival More Accurately than Does Recurrence Score in HER2-Positive Breast Cancer (I-SPY 2)

Journal of Clinical Oncology (2020)

Demonstrates pathological complete response as a robust surrogate for long-term survival in I-SPY 2 adaptive neoadjuvant trials.

[2]

Chemotherapy Response and Recurrence-Free Survival in Neoadjuvant HER2-Positive Breast Cancer with or without Pertuzumab (I-SPY 2)

JAMA Oncology (2021)

I-SPY 2 platform result showing superior outcomes with pertuzumab addition in HER2-positive subtypes using adaptive biomarker-based design.

🏆Awards & Recognition 奖项与荣誉

🏆NIH Director's Pioneer Award
🏆Susan G. Komen Brinker Award for Scientific Distinction
🏆American Surgical Association Distinguished Fellow
🏆ASCO Breast Cancer Symposium Keynote Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 劳拉·埃斯曼 的研究动态

Follow Laura Esserman's research updates

留下邮箱,当我们发布与 Laura Esserman(University of California, San Francisco (UCSF))相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment